Fox Chase Cancer Center News

U.S. News' 2026-2027 “Best Hospitals” rankings placed Fox Chase at No. 11 nationally for its delivery of urology care, the best of any program in the Philadelphia region, and the specialty’s highest ranking in Fox Chase Cancer Center’s history.

Fox Chase Cancer Center ranked No. 32 in the nation according to U.S. News & World Report's 2026-27 Best Hospitals list, with five key areas rated as "High Performing," and urology ranked No.11 nationally.

More than 100 community members, cancer survivors, advocates, researchers, healthcare professionals, and public health leaders gathered at the Lewis Katz School of Medicine at Temple University for the Philadelphia Communities Conquering Cancer (PC3) City Wide Cancer Conference.

Fox Chase Cancer Center’s Mobile Screening Program plays a vital role in delivering cancer screening and prevention services directly to communities throughout Southeastern Pennsylvania. By delivering care outside traditional clinical settings, the program helps address barriers such as transportation challenges, inflexible work schedules, and lack of insurance.

As he begins his new role as Cancer Center Director, Dr. Winn sees Fox Chase in position to shape the future of cancer research both in the local community and beyond - and that a new era of progress will depend on strong partnerships, new approaches to data and technology, and a deeper understanding of the communities served by cancer centers.

"When I say my story is one of hope, I really mean it. I’ve gotten a front-row seat to not theoretically seeing the importance of science, but literally seeing that the research we do can grow to scale and have not just positive clinical outcomes, but real and lasting impact in communities."

Fox Chase Cancer Center's 3,000th bone marrow transplant marks nearly four decades of specialized care for patients with blood cancers.

Temple Health’s Fox Chase Cancer Center, one of only 57 NCI-designated comprehensive cancer centers, announced a new clinical trial collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services. The study will evaluate Labcorp Plasma Detect Genome MRD, a highly sensitive, tumor-informed, whole-genome sequencing-based test, to assess risk of recurrence in patients with early-stage non-small cell lung cancer.